Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism

Affiliations

• 1 Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
• 2 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
• 3 Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
• 4 Department of Oncologic Pathology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA.
• 5 Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
• 6 Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.
• 7 Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
• 8 Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, LMU Munich, Munich, Germany.
• 9 The Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
• 10 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• 11 Department of Medicine, Harvard Medical School, Boston, MA, USA.
• 12 Harvard College, Cambridge, MA, USA.
• 13 Department of Chemistry, University of Vermont, Burlington, VT, USA.
• 14 The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.
• 15 Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
• 16 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
• # Contributed equally.